This is a working overview of Synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-31. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The Frankland-Duppa Reaction in which an oxalate ester (ROCOCOOR) reacts with an alkyl halide R'X, zinc and hydrochloric acid to form α-hydroxycarboxylic esters RR'COHCOOR Organozincs have similar reactivity to Grignard reagents but are much less nucleophilic, and they are expensive and difficult to handle. Organozincs typically perform nucleophilic addition on electrophiles such as aldehydes, which are then reduced to alcohols. Commercially available diorganozinc compounds include dimethylzinc, diethylzinc and diphenylzinc. Like Grignard reagents, organozincs are commonly produced from organobromine precursors. Zinc has found many uses in catalysis in organic synthesis including enantioselective synthesis, being a cheap and readily available alternative to precious metal complexes. Quantitative results (yield and enantiomeric excess) obtained with chiral zinc catalysts can be comparable to those achieved with palladium, ruthenium, iridium and others.
Consequent to the Sino-Soviet split, the pragmatic China established politics of détente with the United States in an effort to publicly challenge the Soviet Union for leadership of the international Marxist–Leninist movement. Mao Zedong's pragmatism permitted geopolitical rapprochement and eventually facilitated President Richard Nixon's 1972 visit to China which subsequently ended the policy of the existence to Two Chinas when the United States sponsored the People's Republic of China to replace the Republic of China (Taiwan) as the representative of the Chinese people at the United Nations. In the due course of Sino-American rapprochement, China also assumed membership in the Security Council of the United Nations. In the post-Mao period of Sino-American détente, the Deng Xiaoping government (1982–1987) affected policies of economic liberalisation that allowed continual growth for the Chinese economy. The ideological justification is socialism with Chinese characteristics, the Chinese adaptation of Marxism–Leninism.
=== Carbon nanotubes and related materials === The technique has been well utilized in studying carbon nanotubes to determine thermodynamic binding interactions with biological molecules and graphene composite interactions. Another notable use of ITC with carbon nanotubes is optimization of preparation of carbon nanotubes from graphene composite and polyvinyl alcohol (PVA). PVA assembly process can be measured thermodynamically as mixing of the two ingredients is an exothermic reaction, and its binding trend can be easily observed by ITC.
Nanoparticles present possible dangers, both medically and environmentally. Most of these are due to the high surface to volume ratio, which can make the particles very reactive or catalytic. They are also thought to aggregate on phospholipid bilayers and pass through cell membranes in organisms, and their interactions with biological systems are relatively unknown. However, it is unlikely the particles would enter the cell nucleus, Golgi complex, endoplasmic reticulum or other internal cellular components due to the particle size and intercellular agglomeration. A recent study looking at the effects of ZnO nanoparticles on human immune cells has found varying levels of susceptibility to cytotoxicity. There are concerns that pharmaceutical companies, seeking regulatory approval for nano-reformulations of existing medicines, are relying on safety data produced during clinical studies of the earlier, pre-reformulation version of the medicine. This could result in regulatory bodies, such as the FDA, missing new side effects that are specific to the nano-reformulation. However considerable research has demonstrated that zinc nanoparticles are not absorbed into the bloodstream in vivo. Concern has also been raised over the health effects of respirable nanoparticles from certain combustion processes. Preclinical investigations have demonstrated that some inhaled or injected noble metal nano-architectures avoid persistence in organisms. As of 2013 the U.S. Environmental Protection Agency was investigating the safety of the following nanoparticles:
Sources: en.wikipedia.org
Archaeol's biosynthesis proceeds by a multistep process mediated by several enzymes. In simplified terms, glycerol 1-phosphate is etherified to two geranylgeranyl substituents contributed by geranylgeranyl pyrophosphate. The double bonds are reduced by nicotinamide and flavins. The phosphate group is subject to modification. Archaea utilize biosynthetic pathways of isoprenoids that is distinct compared to bacteria and eukarya. The C5 precursors to the geranylgeranyl chains are isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are produced by modified mevalonic acid pathway.
One test is for antibodies against the acetylcholine receptor; the test has a reasonable sensitivity of 80–96%, but in ocular myasthenia, the sensitivity falls to 50%. A proportion of the people without antibodies against the acetylcholine receptor have antibodies against the MuSK protein. Less than 1% of patients with myasthenia gravis have antibodies against low-density lipoprotein receptor-related protein 4 (i.e., LRP4). In suspicious situations, testing can be performed for the similar symptomatic Lambert-Eaton syndrome.
1993/528) Legal Aid in Contempt of Court Proceedings (Scotland) (Fees) Amendment Regulations 1993 (S.I. 1993/529) Criminal Legal Aid (Scotland) (Fees) Amendment Regulations 1993 (S.I. 1993/530) Civil Legal Aid (Scotland) (Fees) Amendment Regulations 1993 (S.I. 1993/531) Criminal Legal Aid (Scotland) Amendment Regulations 1993 (S.I. 1993/532) Advice and Assistance (Scotland) Amendment Regulations 1993 (S.I. 1993/533) Legal Aid (Scotland) (Children) Amendment Regulations 1993 (S.I. 1993/534) Civil Legal Aid (Scotland) Amendment Regulations 1993 (S.I. 1993/535) Misuse of Drugs (Licence Fees) (Amendment) Regulations 1993 (S.I. 1993/539) National Health Service (General Medical Services) Amendment Regulations 1993 (S.I. 1993/540) Statistics of Trade (Customs and Excise) (Amendment) Regulations 1993 (S.I. 1993/541) Non-Domestic Rating (Definition of Domestic Property) Order 1993 (S.I. 1993/542) Education (Teachers) Regulations 1993 (S.I. 1993/543) Non-Domestic Rating (Miscellaneous Provisions) (No. 2) (Amendment) Regulations 1993 (S.I. 1993/544) Local Authorities (Members' Allowances) (Amendment) Regulations 1993 (S.I. 1993/545) Building Societies (General Charge and Fees) Regulations 1993 (S.I. 1993/546) Friendly Societies (General Charge and Fees) Regulations 1993 (S.I. 1993/547) Industrial and Provident Societies (Credit Unions) (Amendment of Fees) Regulations 1993 (S.I. 1993/548) Industrial and Provident Societies (Amendment of Fees) Regulations 1993 (S.I.
=== Similar species === In Europe, the spring-fruiting Amanita verna is a similar all-white species, as is the autumn-fruiting, white form of Amanita phalloides (deathcap). Both are equally poisonous. In their immature, button-mushroom stage, all these poisonous species could be mistaken for young, white-capped, edible mushrooms (Agaricus species), highlighting the danger of picking immature fruit bodies for food. In general, there are about 22 species that are considered destroying angels.
==== Documentaries ==== Peyote to LSD: A Psychedelic Odyssey (2008), a History Channel documentary, covers mescaline. Hamilton's Pharmacopeia (2016–2021) has multiple episodes on mescaline in the form of peyote and the San Pedro cactus. How to Change Your Mind (2022) features an episode on mescaline.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.